Evidence map›Paper›PMID 39654394›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2024

Evaluation of hydrazone and

Marija Bartolić, Ana Matošević, Nikola Maraković, Valentina Bušić, Sunčica Roca, Dražen Vikić-Topić, Antonio Sabljić, Anita Bosak, Dajana Gašo-Sokač

Abstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Different packing motifs mediated by hydrogen bonds in the hydro-chloride salts of two pyridoxalActa crystallographica. Section E, Crystallographic communications · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marija BartolićDivision of Toxicology, Institute for Medical Research and Occupational Health, Zagreb, Croatia.
Ana MatoševićDivision of Toxicology, Institute for Medical Research and Occupational Health, Zagreb, Croatia.
Nikola MarakovićDivision of Toxicology, Institute for Medical Research and Occupational Health, Zagreb, Croatia.
Valentina BušićFaculty of Food and Technology Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
Sunčica RocaNMR Centre, Rudjer Bošković Institute, Zagreb, Croatia.
Dražen Vikić-TopićNMR Centre, Rudjer Bošković Institute, Zagreb, Croatia.
Antonio SabljićFaculty of Food and Technology Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
Anita BosakDivision of Toxicology, Institute for Medical Research and Occupational Health, Zagreb, Croatia.
Dajana Gašo-SokačFaculty of Food and Technology Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The growing prevalence of Alzheimer's disease calls for a drug that can simultaneously act towards several targets involved in the pathophysiology of the disease. In our study, we evaluated the potential of hydrazone and

Indexed as

Alzheimer DiseaseCholinesterase InhibitorsHydrazonesPyridinesVitamin B 6AcetylcholinesteraseAmyloid beta-PeptidesAntioxidantsButyrylcholinesteraseDose-Response Relationship, DrugHumansMolecular StructureStructure-Activity RelationshipAcetylcholinesteraseAmyloid beta-PeptidesAntioxidantsButyrylcholinesteraseCholinesterase InhibitorsHydrazonesPyridinesVitamin B 6amyloid self-aggregationBACE1chelationcholinesteraseN-acylhydrazone

Identifiers

PMID39654394
PMCPMC11633425

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.